Literature DB >> 21659000

Optimising the lymphoma response criteria in the era of targeted therapy.

Anas Younes1, Anton Hagenbeek, Bertrand Coiffier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21659000     DOI： 10.1016/S1470-2045(11)70132-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

Authors:  Bruce D Cheson; John C Byrd; Kanti R Rai; Neil E Kay; Susan M O'Brien; Ian W Flinn; Adrian Wiestner; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

Review 2.  FDG PET/CT imaging as a biomarker in lymphoma.

Authors:  Michel Meignan; Emmanuel Itti; Andrea Gallamini; Anas Younes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

3.  Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

Authors:  Anas Younes; Yasuhiro Oki; R Gregory Bociek; John Kuruvilla; Michelle Fanale; Sattva Neelapu; Amanda Copeland; Daniela Buglio; Ahmed Galal; Jeffrey Besterman; Zuomei Li; Michel Drouin; Tracy Patterson; M Renee Ward; Jessica K Paulus; Yuan Ji; L Jeffrey Medeiros; Robert E Martell
Journal:  Lancet Oncol       Date:  2011-10-25       Impact factor: 41.316

Review 4.  International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Authors:  A Younes; P Hilden; B Coiffier; A Hagenbeek; G Salles; W Wilson; J F Seymour; K Kelly; J Gribben; M Pfreunschuh; F Morschhauser; H Schoder; A D Zelenetz; J Rademaker; R Advani; N Valente; C Fortpied; T E Witzig; L H Sehn; A Engert; R I Fisher; P-L Zinzani; M Federico; M Hutchings; C Bollard; M Trneny; Y A Elsayed; K Tobinai; J S Abramson; N Fowler; A Goy; M Smith; S Ansell; J Kuruvilla; M Dreyling; C Thieblemont; R F Little; I Aurer; M H J Van Oers; K Takeshita; A Gopal; S Rule; S de Vos; I Kloos; M S Kaminski; M Meignan; L H Schwartz; J P Leonard; S J Schuster; V E Seshan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.